Simulations Plus Signs Additional Collaboration Agreement

Simulations Plus, Inc.

announced today that it has signed a collaboration agreement with a top-5 pharmaceutical company to add a transdermal and subcutaneous dosing model within its industry gold standard GastroPlus™ simulation software program. Walt Woltosz, chairman and chief executive officer of Simulations Plus, said, “We're very pleased to announce this second funded collaboration this month, which will extend and enhance the GastroPlus simulation model for drug dosing via transdermal and subcutaneous dosing through a variety of dosage forms. Our funded collaborations enable us to extend the competitive advantage of GastroPlus without the need for Simulations Plus to fund the development directly. These will include skin creams, patches, and microneedles for dosing through the skin, as well as injections below the skin in the subcutaneous model.”